Role of carvedilol controlled-release in cardiovascular disease

References

• Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation119(3), 480–486 (2009).
   PubMed Web of Science ®Google Scholar
• Lee DS, Tu JV, Juurlink DN et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA294(10), 1240–1247 (2005).
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), e25–e146 (2008).
   PubMed Web of Science ®Google Scholar
• Steg PG, Dabbous OH, Feldman LJ et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation109(4), 494–499 (2004).
   PubMed Web of Science ®Google Scholar
• Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med.347(18), 1397–1402 (2002).
   PubMed Web of Science ®Google Scholar
• Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation109(22), 2685–2691 (2004).
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension42(6), 1206–1252 (2003).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Larrabee P, Muller-Beckmann B et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin. Investig.70(Suppl. 1), S105–S113 (1992).
   PubMedGoogle Scholar
• Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur. Heart J.16(Suppl. F), 38–42 (1995).
   PubMed Web of Science ®Google Scholar
• Coreg®, package insert. GlaxoSmithKline Plc, NC, USA.
   Google Scholar
• Coreg CR®, package insert. GlaxoSmithKline Plc, NC, USA.
   Google Scholar
• Packer M, Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med.344(22), 1651–1658 (2001).
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet362(9377), 7–13 (2003).
   PubMed Web of Science ®Google Scholar
• Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet357(9266), 1385–1390 (2001).
   PubMed Web of Science ®Google Scholar
• Bristow MR. Mechanism of action of β-blocking agents in heart failure. Am. J. Cardiol.80(11A), L26–L40 (1997).
   PubMed Web of Science ®Google Scholar
• Nichols AJ, Sulpizio AC, Ashton DJ, Hieble JP, Ruffolo RR Jr. The interaction of the enantiomers of carvedilol with α1- and β1-adrenoceptors. Chirality1(4), 265–270 (1989).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6), 1105–1187 (2007).
   PubMed Web of Science ®Google Scholar
• August P. Initial treatment of hypertension. N. Engl. J. Med.348(7), 610–617 (2003).
   PubMed Web of Science ®Google Scholar
• Torre JJ, Bloomgarden ZT, Dickey RA et al.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of hypertension. Endocr. Pract.12(2), 193–222 (2006).
   PubMedGoogle Scholar
• Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol.46(6), E1–E82 (2005).
   PubMed Web of Science ®Google Scholar
• Metra M, Nodari S, Bordonali T et al. Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results. Ther. Clin. Risk Manag.3(4), 569–578 (2007).
   PubMedGoogle Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet353(9146), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet353(9169), 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• β-blocker Evaluation of Survival Trial Investigators. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med.344(22), 1659–1667 (2001).
   PubMed Web of Science ®Google Scholar
• Colucci WS, Packer M, Bristow MR et al.; US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation94(11), 2800–2806 (1996).
   PubMed Web of Science ®Google Scholar
• Krum H, Roecker EB, Mohacsi P et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. JAMA289(6), 712–718 (2003).
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN et al.; US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med.334(21), 1349–1355 (1996).
   PubMed Web of Science ®Google Scholar
• Packer M, Colucci WS, Sackner-Bernstein JD et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation94(11), 2793–2799 (1996).
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation106(17), 2194–2199 (2002).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail.10(10), 933–989 (2008).
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J.26(3), 215–225 (2005).
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in Type II diabetics without alteration of insulin secretion. Lancet1(8421), 123–126 (1985).
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA291(3), 335–342 (2004).
   PubMed Web of Science ®Google Scholar
• Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation110(5), 588–636 (2004).
   PubMed Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction –summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol.40(7), 1366–1374 (2002).
   PubMed Web of Science ®Google Scholar
• Spencer FA, Meyer TE, Gore JM, Goldberg RJ. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation105(22), 2605–2610 (2002).
   PubMed Web of Science ®Google Scholar
• Lainscak M, Cleland JG, Lenzen MJ et al. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur. J. Heart Fail.9(3), 292–299 (2007).
   PubMed Web of Science ®Google Scholar
• Ansari M, Shlipak MG, Heidenreich PA et al. Improving guideline adherence: a randomized trial evaluating strategies to increase β-blocker use in heart failure. Circulation107(22), 2799–2804 (2003).
   PubMed Web of Science ®Google Scholar
• Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev. Cardiovasc. Med.4(Suppl. 7), S21–S30 (2003).
   PubMedGoogle Scholar
• Fonarow GC. Strategies to improve the use of evidence-based heart failure therapies. Rev. Cardiovasc. Med.6(Suppl. 2), S32–S42 (2005).
   PubMedGoogle Scholar
• Fonarow GC, Stevenson LW, Walden JA et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J. Am. Coll. Cardiol.30(3), 725–732 (1997).
   PubMed Web of Science ®Google Scholar
• Whellan DJ, Gaulden L, Gattis WA et al. The benefit of implementing a heart failure disease management program. Arch. Intern. Med.161(18), 2223–2228 (2001).
   PubMedGoogle Scholar
• Gattis WA, O’Connor CM. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. Am. J. Cardiol.93(9A), B74–B76 (2004).
   Google Scholar
• Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J. Am. Coll. Cardiol.43(9), 1534–1541 (2004).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am. Heart J.148(1), 43–51 (2004).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA297(1), 61–70 (2007).
   PubMed Web of Science ®Google Scholar
• Eagle KA, Kline-Rogers E, Goodman SG et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am. J. Med.117(2), 73–81 (2004).
   PubMed Web of Science ®Google Scholar
• Masoudi FA, Baillie CA, Wang Y et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch. Intern. Med.165(18), 2069–2076 (2005).
   PubMedGoogle Scholar
• Bennett SJ, Huster GA, Baker SL et al. Characterization of the precipitants of hospitalization for heart failure decompensation. Am. J. Crit. Care7(3), 168–174 (1998).
   PubMedGoogle Scholar
• Leventhal MJ, Riegel B, Carlson B, De Geest S. Negotiating compliance in heart failure: remaining issues and questions. Eur. J. Cardiovasc. Nurs.4(4), 298–307 (2005).
   PubMedGoogle Scholar
• Horwitz RI, Viscoli CM, Berkman L et al. Treatment adherence and risk of death after a myocardial infarction. Lancet336(8714), 542–545 (1990).
   PubMed Web of Science ®Google Scholar
• Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin. Pharmacother.7(18), 2533–2546 (2006).
   PubMed Web of Science ®Google Scholar
• Kardas P. Comparison of once daily versus twice daily oral nitrates in stable angina pectoris. Am. J. Cardiol.94(2), 213–216 (2004).
   PubMed Web of Science ®Google Scholar
• Kramer JM, Hammill B, Anstrom KJ et al. National evaluation of adherence to β-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am. Heart J.152(3), 454.e1–454.e8 (2006).
   Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther.23(8), 1296–1310 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng JW, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy21(7), 828–841 (2001).
   PubMed Web of Science ®Google Scholar
• Aurich-Barrera B, Wilton LV, Shakir SA. Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. Drug Saf.32(1), 43–54 (2009).
   PubMed Web of Science ®Google Scholar
• Lainscak M, Moullet C, Schon N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int. J. Cardiol.122(2), 149–155 (2007).
   PubMed Web of Science ®Google Scholar
• Opasich C, Boccanelli A, Cafiero M et al. Programme to improve the use of β-blockers for heart failure in the elderly and in those with severe symptoms: results of the BRING-UP 2 Study. Eur. J. Heart Fail.8(6), 649–657 (2006).
   PubMed Web of Science ®Google Scholar
• Mariani M, Vella G, Bianchi C et al. Implementation of β-blockade in elderly heart failure patients: role of the nurse specialist. Eur. J. Cardiovasc. Nurs.7(3), 196–203 (2008).
   PubMed Web of Science ®Google Scholar
• Fowler MB, Lottes SR, Nelson JJ et al. β-blocker dosing in community-based treatment of heart failure. Am. Heart J.153(6), 1029–1036 (2007).
   PubMed Web of Science ®Google Scholar
• Nul D, Zambrano C, Diaz A et al. Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry. Cardiovasc. Drugs Ther.19(2), 125–134 (2005).
   PubMed Web of Science ®Google Scholar
• Egan BM, Basile J, Chilton RJ, Cohen JD. Cardioprotection: the role of β-blocker therapy. J. Clin. Hypertens. (Greenwich)7(7), 409–416 (2005).
   PubMedGoogle Scholar
• Packer M. β-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog. Cardiovasc. Dis.41(1 Suppl. 1), 39–52 (1998).
   PubMed Web of Science ®Google Scholar
• Messerli FH, Grossman E. β-blockers in hypertension: is carvedilol different? Am. J. Cardiol.93(9A), B7–B12 (2004).
   PubMed Web of Science ®Google Scholar
• Packer M. Do β-blockers prolong survival in heart failure only by inhibiting the β1-receptor? A perspective on the results of the COMET trial. J. Card. Fail.9(6), 429–443 (2003).
   PubMed Web of Science ®Google Scholar
• Gilbert EM, Abraham WT, Olsen S et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation94(11), 2817–2825 (1996).
   PubMed Web of Science ®Google Scholar
• Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation101(5), 558–569 (2000).
   PubMed Web of Science ®Google Scholar
• Kozlovski VI, Lomnicka M, Chlopicki S. Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart. Pharmacol. Rep.58(Suppl.), 103–110 (2006).
   PubMedGoogle Scholar
• Yusuf S, Peto R, Lewis J, Collins R, Sleight P. β-blockade during and after myocardial infarction: an overview of the randomized trials. Prog. Cardiovasc. Dis.27(5), 335–371 (1985).
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Port JD, Asano K et al. Cardiac adrenergic receptor effects of carvedilol. Eur. Heart J.17(Suppl. B), 8–16 (1996).
   PubMed Web of Science ®Google Scholar
• Book WM. Carvedilol: a nonselective β blocking agent with antioxidant properties. Congest. Heart Fail.8(3), 173–177, 190 (2002).
   PubMedGoogle Scholar
• Yue TL, McKenna PJ, Gu JL et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension22(6), 922–928 (1993).
   PubMed Web of Science ®Google Scholar
• Toda N. Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol. Ther.100(3), 215–234 (2003).
   PubMed Web of Science ®Google Scholar
• Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J. Hypertens.25(4), 731–741 (2007).
   PubMed Web of Science ®Google Scholar
• Yue TL, McKenna PJ, Gu JL et al. Carvedilol, a new vasodilating β-adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils. Cardiovasc. Res.28(3), 400–406 (1994).
   PubMed Web of Science ®Google Scholar
• Goldhammer E, Maor I, Shnitzer S, Lanir A, Abinader EG. The early anti-oxidant effect of carvedilol predicts the clinical course in congestive heart failure patients. J. Cardiovasc. Med. (Hagerstown)8(6), 453–456 (2007).
   PubMed Web of Science ®Google Scholar
• Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann. Intern. Med.126(12), 955–959 (1997).
   PubMed Web of Science ®Google Scholar
• Maggi E, Marchesi E, Covini D et al. Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J. Cardiovasc. Pharmacol.27(4), 532–538 (1996).
   PubMed Web of Science ®Google Scholar
• Moreno AJ, Santos DJ, Palmeira CM. Ischemic heart disease: the role of mitochondria–carvedilol prevents lipid peroxidation of mitochondrial membranes. Rev. Port. Cardiol.17(Suppl. 2), II63–II77 (1998).
   PubMedGoogle Scholar
• Nakamura K, Kusano K, Nakamura Y et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation105(24), 2867–2871 (2002).
   PubMed Web of Science ®Google Scholar
• Padi SS, Chopra K. Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron92(3), 685–692 (2002).
   PubMed Web of Science ®Google Scholar
• Kurum T, Tatli E, Yuksel M. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy. Tex. Heart Inst. J.34(1), 52–59 (2007).
   PubMed Web of Science ®Google Scholar
• Henderson LS, Tenero DM, Baidoo CA et al. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am. J. Cardiol.98(7A), L17–L26 (2006).
   PubMed Web of Science ®Google Scholar
• Packer M, Lukas MA, Tenero DM, Baidoo CA, Greenberg BH. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am. J. Cardiol.98(7A), L39–L45 (2006).
   PubMed Web of Science ®Google Scholar
• Tenero DM, Henderson LS, Baidoo CA et al. Pharmacokinetic properties of a new controlled-release formulation of carvedilol. Am. J. Cardiol.98(7A), L5–L16 (2006).
   PubMed Web of Science ®Google Scholar
• Henderson LS, Tenero DM, Campanile AM, Baidoo CA, Danoff TM. Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol. J. Clin. Pharmacol.47(11), 1358–1365 (2007).
   PubMed Web of Science ®Google Scholar
• Sundberg S, Tiihonen K, Gordin A. Vasodilatory effects of carvedilol and pindolol. J. Cardiovasc. Pharmacol.10(Suppl 11), S76–S80 (1987).
   PubMed Web of Science ®Google Scholar
• Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a β-adrenoceptor antagonist with unique characteristics. Drugs67(8), 1097–1107 (2007).
   PubMed Web of Science ®Google Scholar
• Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet364(9446), 1684–1689 (2004).
   PubMed Web of Science ®Google Scholar
• Haenni A, Lithell H. Treatment with a β-blocker with β2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism43(4), 455–461 (1994).
   PubMed Web of Science ®Google Scholar
• Jacob S, Rett K, Wicklmayr M et al. Differential effect of chronic treatment with two β-blocking agents on insulin sensitivity: the carvedilol–metoprolol study. J. Hypertens.14(4), 489–494 (1996).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Fonseca V, Katholi RE et al. Metabolic effects of carvedilol vs metoprolol in patients with Type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA292(18), 2227–2236 (2004).
   PubMed Web of Science ®Google Scholar
• Stranders I, Diamant M, van Gelder RE et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch. Intern. Med.164(9), 982–988 (2004).
   PubMed Web of Science ®Google Scholar
• Basat O, Ucak S, Seber S, Oztekin E, Altuntas Y. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin. Res. Cardiol.95(2), 99–104 (2006).
   PubMedGoogle Scholar
• Clodi M, Resl M, Stelzeneder D et al. Interactions of glucose metabolism and chronic heart failure. Exp. Clin. Endocrinol. Diabetes117(3), 99–106 (2009).
   PubMed Web of Science ®Google Scholar
• Doehner W, Rauchhaus M, Ponikowski P et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J. Am. Coll. Cardiol.46(6), 1019–1026 (2005).
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Giles TD, Klibaner M et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am. Heart J.149(1), 159–167 (2005).
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Metra M, Charlesworth A et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart93(8), 968–973 (2007).
   PubMed Web of Science ®Google Scholar
• Kovacic D, Marinsek M, Gobec L, Lainscak M, Podbregar M. Effect of selective and non-selective β-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin. Res. Cardiol.97(1), 24–31 (2008).
   PubMed Web of Science ®Google Scholar
• Doehner W, Anker SD. β-blockers and glucose metabolism in chronic heart failure: friend or foe? Clin. Res. Cardiol.97(1), 21–23 (2008).
   PubMed Web of Science ®Google Scholar
• Berry C, Clark AL. Catabolism in chronic heart failure. Eur. Heart J.21(7), 521–532 (2000).
   PubMedGoogle Scholar
• Anker SD, Negassa A, Coats AJ et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet361(9363), 1077–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Horwich TB, Oreopoulos A et al. Risk factor paradox in wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care10(4), 433–442 (2007).
   PubMed Web of Science ®Google Scholar
• Pocock SJ, McMurray JJ, Dobson J et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur. Heart J.29(21), 2641–2650 (2008).
   PubMed Web of Science ®Google Scholar
• von Haehling S, Horwich TB, Fonarow GC, Anker SD. Tipping the scale: heart failure, body mass index, and prognosis. Circulation116(6), 588–590 (2007).
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Anker SD, Coats AJ, Horwich TB, Fonarow GC. Obesity paradox as a component of reverse epidemiology in heart failure. Arch. Intern. Med.165(15), 1797; author reply 1797–1798 (2005).
   Google Scholar
• Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with β-blockers: a pilot study. Int. J. Cardiol.106(3), 319–322 (2006).
   PubMed Web of Science ®Google Scholar
• Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: β-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension37(2), 250–254 (2001).
   PubMed Web of Science ®Google Scholar
• Sagar UN, Ahmed MM, Adams S, Whellan DJ. Does body mass index really matter in the management of heart failure?: a review of the literature. Cardiol. Rev.16(3), 124–128 (2008).
   PubMed Web of Science ®Google Scholar
• Shirley S, Davis LL, Carlson BW. The relationship between body mass index/body composition and survival in patients with heart failure. J. Am. Acad. Nurse Pract.20(6), 326–332 (2008).
   PubMedGoogle Scholar
• Podbregar M, Voga G. Effect of selective and nonselective β-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J. Card. Fail.8(6), 369–378 (2002).
   PubMed Web of Science ®Google Scholar
• De Leeuw PW, Gaillard CA, Birkenhager WH. Renal hemodynamic patterns in essential hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management. Laragh JH, Brenner BM (Eds). Raven Press Ltd, NY, USA, 1857–1867 (1995).
   Google Scholar
• Tomita K, Marumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. J. Cardiovasc. Pharmacol.19(Suppl. 1), S97–S101 (1992).
   PubMed Web of Science ®Google Scholar
• Dupont AG. Effects of carvedilol on renal function. Eur. J. Clin. Pharmacol.38(Suppl. 2), S96–S100 (1990).
   PubMed Web of Science ®Google Scholar
• Heitmann M, Davidsen U, Stokholm KH et al. Renal and cardiac function during α1-β-blockade in congestive heart failure. Scand. J. Clin. Lab. Invest.62(2), 97–104 (2002).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Hart P, Ritz E. β blockers in the management of chronic kidney disease. Kidney Int.70(11), 1905–1913 (2006).
   PubMed Web of Science ®Google Scholar
• Bakris GL, Tarka EA, Waterhouse B et al. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am. J. Cardiol.98(7A), L46–L52 (2006).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using β-blockers: a critical review of the evidence. J. Am. Coll. Cardiol.50(7), 563–572 (2007).
   PubMed Web of Science ®Google Scholar
• Krum H. Tolerability of carvedilol in heart failure: clinical trials experience. Am. J. Cardiol.93(9A), B58–B63 (2004).
   Google Scholar
• Di Lenarda A, Remme WJ, Charlesworth A et al. Exchange of β-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur. J. Heart Fail.7(4), 640–649 (2005).
   PubMed Web of Science ®Google Scholar
• Krum H, Ninio D, MacDonald P. Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart84(6), 615–619 (2000).
   PubMed Web of Science ®Google Scholar
• Krum H, Hill J, Fruhwald F et al. Tolerability of β-blockers in elderly patients with chronic heart failure: the COLA II study. Eur. J. Heart Fail.8(3), 302–307 (2006).
   PubMed Web of Science ®Google Scholar
• Weber MA, Bakris GL, Tarka EA et al. Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. J. Clin. Hypertens. (Greenwich)8(12), 840–849 (2006).
   PubMedGoogle Scholar
• Weber MA, Sica DA, Tarka EA et al. Controlled-release carvedilol in the treatment of essential hypertension. Am. J. Cardiol.98(7A), L32–L38 (2006).
   PubMed Web of Science ®Google Scholar
• Fonarow GC. β-blockers for the post-myocardial infarction patient: current clinical evidence and practical considerations. Rev. Cardiovasc. Med.7(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• McMurray J, Kober L, Robertson M et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J. Am. Coll. Cardiol.45(4), 525–530 (2005).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Fowler MB, Bristow MR et al.; The US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure. J. Card. Fail.3(3), 173–179 (1997).
   PubMedGoogle Scholar
• Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N; Australia–New Zealand Heart Failure Research Collaborative Group. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J. Am. Coll. Cardiol.29(5), 1060–1066 (1997).
   PubMed Web of Science ®Google Scholar
• Doughty RN, Whalley GA, Walsh HA et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation109(2), 201–206 (2004).
   PubMed Web of Science ®Google Scholar
• Australia–New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation92(2), 212–218 (1995).
   PubMed Web of Science ®Google Scholar
• Australia–New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet349(9049), 375–380 (1997).
   PubMed Web of Science ®Google Scholar
• Torp-Pedersen C, Poole-Wilson PA, Swedberg K et al. Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure – COMET. Am. Heart J.149(2), 370–376 (2005).
   PubMed Web of Science ®Google Scholar
• Stoschitzky K, Stoschitzky G, Brussee H, Bonelli C, Dobnig H. Comparing β-blocking effects of bisoprolol, carvedilol and nebivolol. Cardiology106(4), 199–206 (2006).
   PubMed Web of Science ®Google Scholar
• Pedersen ME, Cockcroft JR. The vasodilatory β-blockers. Curr. Hypertens. Rep.9(4), 269–277 (2007).
   PubMed Web of Science ®Google Scholar
• Greenberg BH, Mehra M, Teerlink JR et al. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. Am. J. Cardiol.98(7A), L53–L59 (2006).
   PubMed Web of Science ®Google Scholar
• Coletta AP, Clark AL, Cleland JG. Clinical trials update from the Heart Failure Society of America and the American Heart Association meetings in 2008: SADHART-CHF, COMPARE, MOMENTUM, thyroid hormone analogue study, HF-ACTION, I-PRESERVE, β-interferon study, BACH, and ATHENA. Eur. J. Heart Fail.11(2), 214–219 (2009).
   PubMedGoogle Scholar
• Greenberg BH. A multicenter, randomized, double-blind, double-dummy, parallel-group study to compare effects of Coreg CR® and Coreg IR® on left ventricular end-systolic volume index in subjects with stable chronic heart failure (COMPARE). Presented at: Heart Failure Society of America 2008 Scientific Meeting.Toronto, ON, Canada, 22 September 2008.
   Google Scholar
• Hauptman PJ, Pressler SJ, Sackner-Bernstein J, Ordronneau P, Udelson JE. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure. Am. J. Cardiol.98(7A), L60–L66 (2006).
   PubMed Web of Science ®Google Scholar
• Udelson JE PS, Sackner-Bernstein J et al. Compliance with once daily controlled release vs twice daily immediate release carvedilol in patients with heart failure: the CASPER trial. J. Card. Fail.13(6 Suppl. 2), S135 (2007).
   Google Scholar
• Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin. Ther.24(2), 302–316 (2002).
   PubMed Web of Science ®Google Scholar
• Wetzels GE, Nelemans P, Schouten JS, Prins MH. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J. Hypertens.22(10), 1849–1855 (2004).
   PubMed Web of Science ®Google Scholar
• Tu W, Morris AB, Li J et al. Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure. Clin. Pharmacol. Ther.77(3), 189–201 (2005).
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians and National Collaboration Centre for Chronic Conditions. Hypertension: Management in Adults in Primary Care: Pharmacological Update. Royal College of Physicians, London, UK (2006).
   Google Scholar
• Abraham WT. Switching between β-blockers in heart failure patients: rationale and practical considerations. Congest. Heart Fail.9(5), 271–278 (2003).
   PubMedGoogle Scholar
• Fonarow GC. Practical considerations of β-blockade in the management of the post-myocardial infarction patient. Am. Heart J.149(6), 984–993 (2005).
   PubMed Web of Science ®Google Scholar